TP53 and plasma cell myeloma: Other reports have shown that sensitivity to proteasome inhibition was partially dependent on the p53 status of the breast [50] and lung cancers in vitro [47], but Bortezomib-induced apoptosis was p53 independent in prostate cancer cells [14], multiple myeloma [15], and colon cancer cells [51].